When a Greek-born Doctor of Veterinarian Medicine tells you that a vaccine is coming to America in March to prevent the Omicron version of COVID-19, you would normally respond with “Quack! Quack!”
But if that doc is also the CEO of Pfizer – Albert Bourla – you should cringe and realize another jab is coming.
Full disclosure: my financial guru – Ben D. – suggested I might as well buy shares in Pfizer, because revenues will zoom in coming months and years. He explained that even if I’m gouged by prices for treatment, I can make up some of that with stock profits.
Will the booster daze ever end?
The CDC has announced that we are a week away from the agency authorizing the fourth vaccine shot, which will be the second booster, following the two jabs for “full” protection. When the push comes this Spring for the Pfizer Omicron injection, many Americans will endured five painful pokes.
Club for Growth star Bourla is very proud of this latest profit-generator:
“It will have way, way better protection, particularly against infection,” he said, arguing the new vaccine will not only be effective against Omicron, but also versus other variants.
Bourla is not the only happy camper at the world’s largest drug manufacturer. His buddy, Frank D’Amelio, Pfizer’s now-retired CFO, said on an earnings call last year that the $19.50 price per dose “is clearly pandemic pricing” compared to what they typically charge for a vaccine.
President Joe Biden agreed and pushed the government to increase that price to $24, while ordering hundreds of millions of doses.
Sadly for the American taxpayer, D’Amelio lifted the curtain on Pfizer’s future vaccine plans, maintaining the price should be $150 to $175. At that price the new vaccine in March for Omicron would set Americans back $49.5 billion at $150 each for full coverage – some 330 million injections.
That $49.5 billion is more than we spend on the General Services Administration ($2.25B), Legislative Branch ($6.1B) Small Business Administration ($9.6B), National Science Foundation ($10.5B) and Department of the Interior ($21B) – combined!
At a recommended two doses annually – every six months – Pfizer’s haul would be $99 billion, an astronomical sum higher than budgeted in 2022 for the Department of Homeland Security (DHS), which includes 230,000 employees in the following departments:
- Federal Emergency Management Agency
- FEMA Disaster Assistance
- Transportation Security Administration
- U.S. Coast Guard
- Computer Emergency Readiness Team
- Federal Law Enforcement Training Center
- Secret Service
- U.S. Immigration and Customs Enforcement
- U.S. Citizenship and Immigration Services
- U.S. Customs and Border Protection
- Federal Protective Service
- Cybersecurity and Infrastructure Security Agency
Meanwhile, the Centers for Disease Control and Prevention (CDC) last week downplayed the dangers from the COVID virus and its strains if you survived the initial two shots.
Researchers looked at more than one million fully-vaccinated people between December 2020 and October 2021 to find even among those with a risk factor, the likelihood of severe disease was a rare 0.0033 percent factor for severe outcomes – over the age of 65, the immune-suppressed, and those with six other underlying conditions.
The study found that 78 percent of the people to die from COVID-19 after receiving the vaccine had at least four other underlying health conditions. It also found that, in all deaths, the patient had at least one other risk factor.